Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
PHYRAGO (DASATINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
PHYRAGO
NDA
Get alerts
DASATINIB | N216099 | HANDA THERAPEUTICS LLC
6 strengths
6 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
6 unique patents, 1 exclusivity by expiration date
All strengths
20MG
50MG
70MG
80MG
100MG
140MG
Active (6)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
11202778
Jan. 22, 2041
11298356
Jan. 22, 2041
11324745
Jan. 22, 2041
12433891
Jan. 22, 2041
12465606
Jan. 22, 2041
12544376
Jan. 22, 2041
M-307
Dec. 5, 2026
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (6)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 20MG
RLD
6 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Dec 5, 2023
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11202778
Jan 22, 2041
—
—
—
U-3770
USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
—
11298356
Jan 22, 2041
—
—
Yes
—
—
11324745
Jan 22, 2041
—
—
—
U-3767
USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
—
12433891
Jan 22, 2041
—
—
—
U-3769
USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
—
12465606
Jan 22, 2041
—
—
Yes
—
—
12544376
Jan 22, 2041
—
—
—
U-3767
USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
—
Exclusivities (1)
Code
Date
Status
M-307
Dec 5, 2026
< 1 year
#002 — 50MG
RLD
6 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Dec 5, 2023
#003 — 70MG
RLD
6 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Dec 5, 2023
#004 — 80MG
RLD
6 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Dec 5, 2023
#005 — 100MG
RLD
6 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Dec 5, 2023
#006 — 140MG
RLD
6 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Dec 5, 2023